193 related articles for article (PubMed ID: 35058488)
1. Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.
Quentmeier H; Geffers R; Hauer V; Nagel S; Pommerenke C; Uphoff CC; Zaborski M; Drexler HG
Sci Rep; 2022 Jan; 12(1):1085. PubMed ID: 35058488
[TBL] [Abstract][Full Text] [Related]
2. Expression Ratios of the Antiapoptotic BCL2 Family Members Dictate the Selective Addiction of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Primary Effusion Lymphoma Cell Lines to MCL1.
Dunham D; Viswanathan P; Gill J; Manzano M
J Virol; 2022 Dec; 96(23):e0136022. PubMed ID: 36416587
[TBL] [Abstract][Full Text] [Related]
3. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
S Soderquist R; Eastman A
Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
[TBL] [Abstract][Full Text] [Related]
4. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
[TBL] [Abstract][Full Text] [Related]
5. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
[No Abstract] [Full Text] [Related]
7. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
Prutsch N; Gurnhofer E; Suske T; Liang HC; Schlederer M; Roos S; Wu LC; Simonitsch-Klupp I; Alvarez-Hernandez A; Kornauth C; Leone DA; Svinka J; Eferl R; Limberger T; Aufinger A; Shirsath N; Wolf P; Hielscher T; Sternberg C; Aberger F; Schmoellerl J; Stoiber D; Strobl B; Jäger U; Staber PB; Grebien F; Moriggl R; Müller M; Inghirami GG; Sanda T; Look AT; Turner SD; Kenner L; Merkel O
Leukemia; 2019 Mar; 33(3):696-709. PubMed ID: 30131584
[TBL] [Abstract][Full Text] [Related]
8. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
Mallick DJ; Soderquist RS; Bates D; Eastman A
Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
[TBL] [Abstract][Full Text] [Related]
9. BCL2 and MCL1 inhibitors for hematologic malignancies.
Roberts AW; Wei AH; Huang DCS
Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors.
Voutsadakis IA
Gene; 2022 Dec; 847():146881. PubMed ID: 36100115
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
12. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
16. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.
Koch R; Christie AL; Crombie JL; Palmer AC; Plana D; Shigemori K; Morrow SN; Van Scoyk A; Wu W; Brem EA; Secrist JP; Drew L; Schuller AG; Cidado J; Letai A; Weinstock DM
Blood; 2019 Feb; 133(6):566-575. PubMed ID: 30498064
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
19. YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma.
Kojima Y; Hayakawa F; Morishita T; Sugimoto K; Minamikawa Y; Iwase M; Yamamoto H; Hirano D; Imoto N; Shimada K; Okada S; Kiyoi H
Pharmacol Res; 2017 Jun; 120():242-251. PubMed ID: 28396094
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
Subramanian A; Andronache A; Li YC; Wade M
Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
